Los avances en nuestro conocimiento de las enfermedades del hígado en la última década son impresionantes Pero seguimos teniendo una gran asignatura pendiente con la enfermedad hepática asociada al #alcohol
https://www.journal-of-hepatology.eu/article/S0168-8278(23)00308-2/fulltext
The future of hepatology – “The best way to predict the future is to create it”
References
- Shrank W.H.
- Rogstad T.L.
- Parekh N.
Waste in the US health care system: estimated costs and potential for savings.JAMA. 2019; 322: 1501-1509- Ahn J.C.
- Connell A.
- Simonetto D.A.
- Hughes C.
- Shah V.H.
Application of artificial intelligence for the diagnosis and treatment of liver diseases.Hepatology. 2021; 73: 2546-2563- Kim H.Y.
- Lampertico P.
- Nam J.Y.
- Lee H.C.
- Kim S.U.
- Sinn D.H.
- et al.
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.J Hepatol. 2022; 76: 311-318- Penrice D.D.
- Rattan P.
- Simonetto D.A.
Artifical intelligence and the future of gastroenterology and hepatology.Gastro Hep Adv. 2022; 1: 581-595- Beam A.L.
- Manrai A.K.
- Ghassemi M.
Challenges to the reproducibility of machine learning models in health care.JAMA. 2020; 323: 305-306- Shachar C.
- Gerke S.
Prevention of bias and discrimination in clinical practice algorithms.JAMA. 2023; 329: 283-284- Vargason A.M.
- Anselmo A.C.
- Mitragotri S.
The evolution of commercial drug delivery technologies.Nat Biomed Eng. 2021; 5: 951-967- Yang X.
- Meng Y.
- Han Z.
- Ye F.
- Wei L.
- Zong C.
Mesenchymal stem cell therapy for liver disease: full of chances and challenges.Cell Biosci. 2020; 10: 123- Cao J.
- Choi M.
- Guadagnin E.
- Soty M.
- Silva M.
- Verzieux V.
- et al.
mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease.Nat Commun. 2021; 12: 3090- Deng Z.
- Yang H.
- Tian Y.
- Liu Z.
- Sun F.
- Yang P.
An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma.Front Oncol. 2022; 12975408- Wei G.
- Cao J.
- Huang P.
- An P.
- Badlani D.
- Vaid K.A.
- et al.
Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.J Hepatol. 2021; 74: 1416-1428- Yuen M.F.
- Heo J.
- Kumada H.
- Suzuki F.
- Suzuki Y.
- Xie Q.
- et al.
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.J Hepatol. 2022; 77: 967-977- Zabaleta N.
- Torella L.
- Weber N.D.
- Gonzalez-Aseguinolaza G.
mRNA and gene editing: late breaking therapies in liver diseases.Hepatology. 2022; 76: 869-887- Araman C.
- Beck-Broichsitter M.
- Erwin N.
- Hafiz S.
- Kasselkus A.
- Kipping T.
- et al.
Seven trends shaping the future of pharmaceutical formulation development.2022- Niu L.
- Thiele M.
- Geyer P.E.
- Rasmussen D.N.
- Webel H.E.
- Santos A.
- et al.
Noninvasive proteomic biomarkers for alcohol-related liver disease.Nat Med. 2022; 28: 1277-1287- Karlsen T.H.
- Sheron N.
- Zelber-Sagi S.
- Carrieri P.
- Dusheiko G.
- Bugianesi E.
- et al.
The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.Lancet. 2022; 399: 61-116- FDA accepts intercept’s new drug application for OCA for the treatment of pre-cirrhotic liver fibrosis due to NASH. 2023 ([press release])
- Madrigal Madrigal.
Announces additional positive results from the pivotal phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH with liver fibrosis.2022- Beudeker B.J.B.
- Boonstra A.
Circulating biomarkers for early detection of hepatocellular carcinoma.Therap Adv Gastroenterol. 2020; 131756284820931734- Bianco C.
- Jamialahmadi O.
- Pelusi S.
- Baselli G.
- Dongiovanni P.
- Zanoni I.
- et al.
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol. 2021; 74: 775-782- Staufer K.
- Huber-Schonauer U.
- Strebinger G.
- Pimingstorfer P.
- Suesse S.
- Scherzer T.M.
- et al.
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.J Hepatol. 2022; 77: 918-930- Israelsen M.
- Juel H.B.
- Detlefsen S.
- Madsen B.S.
- Rasmussen D.N.
- Larsen T.R.
- et al.
Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis.Clin Gastroenterol Hepatol. 2022; 20: 1784-1794 e1789- Gupta P.
- Soundararajan R.
- Patel A.
- Kumar M.P.
- Sharma V.
- Kalra N.
Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis.J Hepatol. 2021; 75: 108-119- Arroyo V.
- Angeli P.
- Moreau R.
- Jalan R.
- Claria J.
- Trebicka J.
- et al.
The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis.J Hepatol. 2021; 74: 670-685- Trebicka J.
- Fernandez J.
- Papp M.
- Caraceni P.
- Laleman W.
- Gambino C.
- et al.
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.J Hepatol. 2020; 73: 842-854- Caraceni P.
- Abraldes J.G.
- Gines P.
- Newsome P.N.
- Sarin S.K.
The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery.J Hepatol. 2021; 75: S118-S134- Pose E.
- Napoleone L.
- Amin A.
- Campion D.
- Jimenez C.
- Piano S.
- et al.
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Gastroenterol Hepatol. 2020; 5: 31-41- Agarwal B.S.F.
- Tomescu D.R.
- Canizares R.B.
- Martin D.
- Stadlbauer V.
- et al.
A multi-centre, randomized controlled study, to evaluate the safety and performance of the DIALIVE liver dialysis device in patients with acute on chronic liver failure (ACLF) versus standard of care (SOC) (ALIVER Consortium).Gut. 2021; 70: A54- Wolffram I.
- Petroff D.
- Batz O.
- Jedrysiak K.
- Kramer J.
- Tenckhoff H.
- et al.
Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios.J Hepatol. 2015; 62: 1256-1264- Francque S.M.
- Marchesini G.
- Kautz A.
- Walmsley M.
- Dorner R.
- Lazarus J.V.
- et al.
Non-alcoholic fatty liver disease: a patient guideline.JHEP Rep. 2021; 3100322- Kummetat J.L.
- Leonhard A.
- Manthey J.
- Speerforck S.
- Schomerus G.
Understanding the association between alcohol stigma and alcohol consumption within europe: a cross-sectional exploratory study.Eur Addict Res. 2022; 28: 446-454- Schomerus G.
- Leonhard A.
- Manthey J.
- Morris J.
- Neufeld M.
- Kilian C.
- et al.
The stigma of alcohol-related liver disease and its impact on healthcare.J Hepatol. 2022; 77: 516-524- Berg T.
- Krag A.
Thriving in turbulent times: EASL reflects on 2021, looking to 2022 and beyond.J Hepatol. 2022; 77: 278-281
Article info
Publication history
Published online: June 12, 2023Accepted: April 21, 2023Received: April 21, 2023Publication stage
In Press Journal Pre-ProofFootnotes
Author names in bold designate shared co-first authorship
Identification
Copyright
© 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.ScienceDirect
Access this article on ScienceDirectRelated Articles
- Impact of non-invasive biomarkers on hepatology practice: Past, present and future
- Anstee et al.
Journal of Hepatology - Evaluating future risk of NAFLD fibrosis in adolescents: prediction and decision curve analysis
- Abeysekera et al.
Journal of Hepatology - Hepatology Genome Rounds: An interdisciplinary approach to integrate genomic data in clinical practice
- Chung et al.
Journal of HepatologyMarch 31, 2023 - Current treatment strategies and future possibilities for sarcopenia in cirrhosis
- Ebadi et al.
Journal of HepatologyFebruary 10, 2023 - Breakthroughs in hepatology
- Terrault et al.
Journal of Hepatology
No hay comentarios:
Publicar un comentario